Last Updated : May 6, 2024
Details
FilesGeneric Name:
Optimal Pharmacotherapy for Transplant-Ineligible Multiple Myeloma
Project Status:
Complete
Project Line:
Reimbursement Review
Project Sub Line:
Therapeutic Review
Project Number:
TR0014-000 - OP0547-000
Effective finish date:
Multiple myeloma (MM) is a hematological cancer that mainly affects individuals older than 65 years of age. Though MM remains incurable, several life-prolonging pharmacotherapies for the treatment of newly diagnosed, relapsed, or refractory MM were reviewed by CADTH and are available or being considered for public reimbursement in Canada. However, at this time, the optimal sequence of therapies is unclear. CADTH completed a Therapeutic Review considering multiple MM drugs and treatment steps in order to help decision-makers develop appropriate pharmaceutical funding policies.
| Draft recommendation(s) posted for stakeholder feedback | January 4, 2024 |
|---|---|
| End of feedback period | January 25, 2024 |
| Updated draft recommendation(s) posted for stakeholder feedback | March 7, 2024 |
| End of updated reimbursement recommendation feedback period | March 21, 2024 |
| Final recommendation decision | November 30, 2023 |
| Date recommendation issued | February 1, 2024 |
| Final summary report posted | April 16, 2024 |
| Final recommendation posted | May 6, 2024 |
| Final updated reimbursement recommendations | May 6, 2024 |
Files
Last Updated : May 6, 2024